title: Future prospects for anti-cytokine treatment.
abstract: The era of anti-cytokine treatment in rheumatology has just begun. The first generation therapeutic agents, biological agents that block tumour necrosis factor alpha such as monoclonal antibodies or receptor Ig fusion proteins are safe and effective, and so this has generated much interest in how to increase the benefit or deliver it more cost effectively. This article provides a personal view of the coming trends in anti-cytokine treatment. Which of these will be realised in the future will be of interest.
authors.affiliation: Kennedy Institute of Rheumatology, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK.
authors.forename: M
authors.initials: M
authors.lastname: Feldmann
authors.forename: J
authors.initials: J
authors.lastname: Miotla
authors.forename: E
authors.initials: E
authors.lastname: Paleolog
authors.forename: R
authors.initials: R
authors.lastname: Williams
authors.forename: A M
authors.initials: AM
authors.lastname: Malfait
authors.forename: P
authors.initials: P
authors.lastname: Taylor
authors.forename: F M
authors.initials: FM
authors.lastname: Brennan
authors.forename: R N
authors.initials: RN
authors.lastname: Maini
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors*; D005544:Forecasting; D006801:Humans
chemical_list: D018501:Antirheumatic Agents; D016207:Cytokines